Customize your search results with filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 02/19/2023

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 211 publications

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Condition: Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: The New England journal of medicine
Treatment Used: Glofitamab
Number of Patients: 155
Published: December 12, 2022

Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma.

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Frontiers in immunology
Treatment Used: Zanubrutinib Plus Salvage Chemotherapy
Number of Patients: 27
Published: December 12, 2022

Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon.

Condition: Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with Hypopyon
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Treatment Used: Busulfan/Thiotepa (BuTT) Followed by Autologous Peripheral Blood Stem Cell Transplantation
Number of Patients: 1
Published: November 09, 2022

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System.

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: JCO global oncology
Treatment Used: Rituximab
Number of Patients: 1807
Published: November 09, 2022

Efficacy of Helicobater pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: A systematic review.

Condition: Diffuse Large B-Cell Lymphoma (DLBCL) of Stomach
Journal: European journal of haematology
Treatment Used: Helicobacter Pylori Eradication
Number of Patients: 152
Published: September 29, 2022

ABCL-310 Triple Metachronous Malignancies in Primary Diagnosed Diffuse Large B-Cell Lymphoma Patient: A Case Report.

Condition: Triple Metachronous Malignancies in Patient with Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Chemotherapy, Splenectomy, and Hemodialysis
Number of Patients: 1
Published: September 27, 2022

ABCL-398 Primary Breast Diffuse Large B-Cell Lymphoma: An Indian Experience.

Condition: Primary Breast Diffuse Large B-Cell Lymphoma (PB-DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Multimodal Combination Therapy
Number of Patients: 18
Published: September 27, 2022

ABCL-388 L-MIND: Safety and Efficacy of Tafasitamab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma on Treatment for at Least 2 Years.

Condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Tafasitamab
Number of Patients: 80
Published: September 27, 2022

ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study.

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP)
Number of Patients: 879
Published: September 27, 2022

ABCL-088 Subgroup Analysis in RE-MIND2: An Observational, Retrospective Cohort Study of Tafasitamab + Lenalidomide Versus Systemic Therapies in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Condition: Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Tafasitamab Plus Lenalidomide (LEN)
Number of Patients: 3454
Published: September 27, 2022

ABCL-320 Initial Safety Run-In Results of the Phase 3 LOTIS-5 Trial: Novel Combination of Loncastuximab Tesirine With Rituximab (Lonca-R) Versus Immunochemotherapy in Patients With R/R DLBCL.

Condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Loncastuximab Tesirine Combined with Rituximab (Lonca-R)
Number of Patients: 20
Published: September 27, 2022

ABCL-452 First-Line Treatment With Subcutaneous Epcoritamab + R-CHOP in Patients With High-Risk Diffuse Large B-Cell Lymphoma (DLBCL): Phase 1/2 Data Update.

Condition: High-Risk Diffuse Large B-Cell Lymphoma (DLBCL)
Journal: Clinical lymphoma, myeloma & leukemia
Treatment Used: Epcoritamab Plus R-CHOP
Number of Patients: 33
Published: September 27, 2022
Showing 1-12 of 211

Last Updated: 02/19/2023